| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992059 | Journal of Thoracic Oncology | 2008 | 6 Pages |
Abstract
In chemotherapy-naive patients with advanced NSCLC and a PS of 2, single agent erlotinib resulted in an acceptable but significant level of treatment-related side effects. With an overall DCR of 42% and median survival of 5 months, results are comparable to those achieved with chemotherapy in this population. Development of an epidermal growth factor receptor-directed biomarker selection strategy may optimize use of erlotinib in PS 2 patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paul J. MD, Kari MS, Antoinette J. MD, Fred R. MD, PhD, Anna MD, James MS, Philip C. PhD, Benjamin T. MD, Wilbur A. MD, John J. PhD, David R. MD,